Tozadenant
RO-449351
SYN-115
- Molecular Formula C19H26N4O4S
- Average mass 406.499 Da
A2 (3); A2a-(3); RO4494351; RO4494351-000; RO4494351-002; SYN-115
Phase III clinical trials at Biotie Therapies for the treatment of Parkinson’s disease as an adjunctive therapy with levodopa
1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-
4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-1,3-benzothiazol-2-yl]-4-methyl-1-piperidinecarboxamide
4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide
4-Hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
CAS 870070-55-6
- Originator Roche
- Developer Acorda Therapeutics
- Class Amides; Antiparkinsonians; Benzothiazoles; Carboxylic acids; Morpholines; Piperidines; Small molecules
- Mechanism of Action Adenosine A2A receptor antagonists
Highest Development Phases
- Phase III Parkinson’s disease
- Phase I Liver disorders
Most Recent Events
- 30 Jun 2017 Biotie Therapies plans a phase I trial in Healthy volunteers in Canada (NCT03200080)
- 30 Jun 2017 Phase-I clinical trials in Liver disorders (In volunteers) in USA (PO) (NCT03212313)
- 27 Apr 2017 Acorda Therapeutics initiates enrolment in a phase III trial for Parkinson’s disease in Germany (EudraCT2016-003961-25)(NCT03051607)
Biotie Therapies Holding , under license from Roche , is developing tozadenant (phase…
View original post 2,958 more words
